0.25Open0.26Pre Close72 Volume3.58K Open Interest4.00Strike Price2.24KTurnover58.93%IV6.39%PremiumDec 20, 2024Expiry Date0.07Intrinsic Value100Multiplier27DDays to Expiry0.26Extrinsic Value100Contract SizeAmericanOptions Type0.5826Delta0.6003Gamma13.57Leverage Ratio-0.0050Theta0.0015Rho7.90Eff Leverage0.0043Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet